For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Argatroban is a synthetic direct thrombin inhibitor and the chemical name is 1-[5- [(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid, monohydrate. Argatroban has 4 asymmetric carbons. One of the asymmetric carbons has an R configuration (stereoisomer Type I) and an S configuration (stereoisomer Type II). Argatroban consists of a mixture of R and S stereoisomers at a ratio of approximately 65:35.
Scope of the Report:
In the last several years, global market of Argatroban Industry decreased with the average production growth rate about -15%. In 2015, global capacity of Argatroban reduced to 34786 grams
from 65183 grams since 2011. It is predicted that the argatroban demand will continue to decrease with a average growth rate of -9% in the coming five years.
Japan is the still largest supplier of argatroban with the production market share of 35% and the consumption market share of 22% in 2015.
The price of argatroban is relatively expensive. The largest consumers are developed countries with high income. USA occupied a market share of 34%. The second place is Europe, following North America with the consumption market share of 22% in 2015.
China has few companies entering the market with production share of only 8%, and demand cannot be satisfied with supply. Large quantities of argatroban have to be imported.
Intially, compared with hirudin and heparin, the therapeutic dose has little effect on platelet, no antigen and strong antithrombotic effect. The sale value has reached 190 million USA dollars in 2008. But because of its narrow therapeutic area, uncertain factors on human's bodies and fierce competition from other substitutes, it sales far less than other thrombin inhibitor. The value reduced to 101 million USA dollars in 2015.
The worldwide market for Argatroban is expected to grow at a CAGR of roughly -14.9% over the next five years, will reach 32 million US$ in 2024, from 84 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Argatroban in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- Pfizer, Inc
- SANDOZ
- GlaxoSmithKline Plc
- fresenius-kabi
- Eagle Pharmaceuticals, Inc
- Mitsubishi Tanabe Pharma
- Teva Pharmaceutical Industries Ltd
- WEST-WARD,INC
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Argatroban Powder
- Argatroban Injection
Market Segment by Applications, can be divided into
- Heparin-induced thrombocytopenia (HIT)
- Percutaneous Coronary Intervention
- Cerebral arterial thrombosis
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Argatroban product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Argatroban, with price, sales, revenue and global market share of Argatroban in 2017 and 2018.
Chapter 3, the Argatroban competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Argatroban breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Argatroban market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Argatroban sales channel, distributors, customers, research findings and conclusion, appendix and data source.